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Summary Jacobson et al. 1989; Meire et al. 1994). Carriers may
show decreased visual acuity and unilateral high myopia
Clinical reexamination and DNA linkage analysis were with amblyopia. Color-vision testing and foveal densi-
carried out in an X-linked progressive cone dystrophy tometry may be useful for carrier detection (Keunen et
(XLPCD) family, previously described by Pinckers and al. 1990; van Everdingen et al. 1992). Especially, a re-
Timmerman in 1981. In a large pedigree segregating duced ERG response elicited by a red-light stimulus ap-
XLPCD, by use of §27 markers spanning the entire X pears to be indicative for carrier state (Meire et al. 1994).
chromosome, a novel locus for XLPCD was identiﬁed XLPCD can be distinguished from another form of
in Xq27. All other regions on the chromosome could be X-linked cone dysfunction, blue cone monochromatism
excluded. Since this novel locus is distinct from pre- (BCM). In contrast with XLPCD, BCM is a congenital,
viously identiﬁed genes or regions involved in XLPCD, nonprogressive disorder in which the function of the
we further establish genetic heterogeneity underlying cones that are sensitive for the blue part of the light
this disease entity. spectrum remain intact.
Linkage analysis in three families assigned an XLPCD
gene to the Xp21.1-p11.3 region, to the region betweenIntroduction
the loci DXS84 and ARAF1 (table 1) (Bartley et al. 1989;
X-linked progressive cone dystrophy (XLPCD) is a he- Hong et al. 1991, 1994; Bergen et al. 1993a). On the
reditary eye disease characterized by photophobia, nys- other hand, BCM and possibly another form of XLPCD
tagmus, loss of visual acuity, abnormal color vision, and were recognized as defects in the green and red cone
disturbed cone electroretinogram (ERG) (Pinckers et al. pigment–gene cluster located in Xq28 (table 1) (Na-
1981; Verdoorn and Pinckers 1988; Pinckers and Deut- thans et al. 1989; Reichel et al. 1989). Here we report
man 1987). Eight families apparently segregating a linkage analysis in an XLPCD family, previously de-
XLPCD have been reported elsewhere (Fleischman and scribed by Pinckers and Timmerman (1981), which sug-
O’Donnell 1981; Pinckers et al. 1981; Pinckers and Tim- gests that the underlying molecular defect is uniquely
merman 1981; Heckenlively and Weleber 1986; Ver- located in Xq27.
doorn and Pinckers 1988; Jacobson et al. 1989; Reichel
et al. 1989; Keunen et al. 1990; Meire et al. 1994).
Patients, Material, and MethodsAccording to these studies, subtle phenotypic differences
exist between families segregating this disorder. Also,
Patientsintrafamiliar differences have been described (Keunen et
The majority of patients were examined by A.J.L.G.P.al. 1990; Hong et al. 1994). An overview of clinical
at the Department of Ophthalmology of the Universitycharacteristics of families for which the genetic locus is
Hospital in Nijmegen. A number of individuals haveknown is presented in table 1.
been examined at the Netherlands Ophthalmic ResearchElectrophysiological examination is required for diag-
Institute and the Groot Ziekengasthuis in Den Boschnosis. The ERG shows attenuated cone-mediated re-
(table 2).sponses in the younger patients, whereas the older af-
The pedigree of the family is presented in ﬁgure 1. Allfected males may also demonstrate rod dysfunction
patients and potential carriers underwent full ophthal-(Pinckers et al. 1981; Heckenlively and Weleber 1986;
mological examination, including refraction and visual
acuity testing, slit-lamp examination, and funduscopy.
In addition, ERG and electrooculography were per-Received December 10, 1996; accepted for publication March 8,
formed. Color vision was tested under standardized con-1997.
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Table 1
Main Clinical Characteristics of XLPCD and BCM for Which Genetic Defect Is Known
DATA FOR DISEASE (GENE NAME)
XLPCD
Xp21.1-p11.2 (COD1) Xq27 (COD2) Xq28 (Not Assigned) BCM, Xq28 (GCP and RCP)
Molecular defect:
Status Assigned by linkage Assigned by linkage analysis Deletion in red Deletion near 5 of red
analysis cone–pigment cone–pigment gene
gene
Reference(s) Bartley et al. (1989); Present study Reichel et al. (1989) Nathans et al. (1989)
Bergen et al. (1993)
Main clinical
characteristics:
General Reduced visual acuity; Early onset; reduced visual Reduced visual Reduced visual acuity;
progressive macular acuity; peripheral cone acuity; progressive normal fundus; nystagmus
atrophy progresses to diffuse type macular atrophy
Color vision Congenital normal, Congenital normal, Congenital Congenital achromatopsia,
progressing to progressing to central protanopia, not progressive
central acquired acquired achromatopsia progressing to
achromatopsia (type (type I Verriest) central acquired
I Verriest) achromatopsia
(type I Verriest)
ERG Reduced cone ERG; in Reduced cone ERG; in later Reduced cone ERG Reduced cone ERG
later stages reduced stages reduced rod ERG
rod ERG
References Jacobson et al. (1989); Pinckers and Timmerman Reichel et al. (1989) Nathans et al. (1989)
Hong et al. (1994); (1981)
Meire et al. (1994)
Molecular and Statistical Studies Results
Southern and PCR analyses were essentially performed
Clinical Studiesas described elsewhere (Bergen et al. 1991, 1993b). Statisti-
The XLPCD segregating in the pedigree presented incal analyses were performed by use of the computer pro-
ﬁgure 1 begins as a peripheral cone disease and progressesgram MLINK from the package LINKAGE 5.1. Markers
to a diffuse cone disease (Pinckers and Timmerman 1981).are registered at the Human Genome Database. An
XLPCD gene frequency of .00001 was used. Affected males exhibit diminished visual acuity, myopia,
Table 2
Clinical Variability within XLPCD Family
Case Visual Acuity Myopia Fundus ERGa Color Visiona
I-1/7 ú.1 08 Atrophy Cone-rod No color perception
I-3/4 ú.1 010 Atrophy Cone-rod No color perception
II-6/1 1.0 05 Myopic Cone Normal
II-16/9 .1 06 Myopic EE Type I, achromatopsia
II-18/15 .8 09 Myopic EE EE
II-21/10 .3 012 Myopic Cone EE
II-25/14 .3 019 Myopic Cone Type I, early stage
III-5/2 .4 04 Myopic Cone Type I, scotopization
III/6/3 1.0 /1 Normal Normal Normal
III-13/16 .4 05 Myopic EE EE
NOTE.—I-4/13, II-5/5, and I-5/8 were examined elsewhere. Only directly comparable clinical on patients
examined by A.J.L.G.P. according to speciﬁc standard procedures are given.
aEEÅ examined elsewhere (i.e., at the Netherlands Ophthalmic Research Institute or the Groot Ziekengas-
thuis in Den Bosch).
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Figure 1 Segregation pattern of a number of X-chromosomal markers in the target region. DXS292Å VK14AC; and DXS297Å VK23AC.
disturbed cone ERG, and a type I color-vision defect. The Reexamination of several family members over the
past 15 years showed a slight progression in the males,type I acquired defect is observed in retinal disease primar-
ily involving the photoreceptors of the posterior pole and whereas the ﬁndings in the heterozygote females re-
mained constant. Clinical variability of the diseaseis assumed to reﬂect a destruction of the macular cones.
In the type I acquired defect the chromatic discrimination within the family is presented in table 2.
on the red and green axis progressively deteriorates. In an
Molecular Studiesadvanced stage, there is total colorblindness in the affected
visual ﬁeld, resembling congenital achromatopsia. The XLPCD pedigree was studied with §27 markers
spanning the entire X chromosome (table 3). Except forHeterozygous females in this XLPCD family have di-
minished visual acuity and myopia but, as a rule, a markers from the Xq27 region, one ormultiple recombina-
tion events were found between each of these markers andnormal cone ERG and normal color vision. The only
nonobligate carrier (II-21) was diagnosed as such be- the disease locus. The segregation of alleles of markers in
the Xq27 region in the family is shown in ﬁgure 1.cause of a diminished visual acuity and high myopia,
which could not be explained otherwise. Close linkage without recombination was found be-
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Table 3
Two-Point Linkage for Markers along Human X Chromosome and XLPCD
MAXIMUM MAXIMUM LOD SCORE AT RECOMBINATION FRACTION OF
RECOMBINATION LOD
LOCUS FRACTION SCORE .00 .01 .05 .10 .20 .30
KAL 0 04.82 02.18 01.16 0.36 0.07
DXS207 0 06.76 03.39 02.04 0.86 0.32
DXS999 0 05.44 02.74 01.66 0.72 0.28
DXS451 0 02.07 0.80 0.35 0.06 0.04
DMD49 0 02.92 0.99 0.33 .08 .13
DYS-I 0 04.31 02.25 01.42 0.66 0.29
DXS1058 0 02.65 01.30 0.76 0.29 0.09
MAOB 0 05.31 02.61 01.53 0.59 0.19
DXS255 0 01.22 .00 .38 .54 .43
DXS14 0 02.81 01.47 0.93 0.45 0.22
DXS453 0 06.13 02.80 01.49 0.45 0.08
DXS441 0 06.37 03.02 01.71 0.06 0.16
DXS1002 0 06.67 03.32 02.01 0.89 0.42
DXS3 0 07.47 04.03 02.61 01.30 0.63
DXS456 0 02.34 0.99 0.46 0.04 .10
DXS1106 0 0.59 .00 .17 .22 .18
DXS424 0 02.14 0.81 0.32 .06 .15
DXS1114 0 .05 .61 .73 .67 .49
DXS984 0 0.8 0.18 0.00 .06 .02
DXS292 0 .73 1.22 1.26 1.03 .68
DXS297 .00 2.54 2.54 2.50 2.29 2.03 1.48 .93
DXS998 .00 2.06 2.06 2.02 1.84 1.61 1.15 .70
DXS1123 .00 2.60 2.60 2.55 2.33 2.07 1.52 .97
DXS1113 03.49 .66 1.15 1.18 .94 .58
DXS52 03.67 .48 .98 1.02 .811 .48
tween the XLPCD locus (COD2) and the loci DXS297, Special attention was given to the segregation patterns
of the markers surrounding the COD1 region in Xp21.1-DXS998, and DXS1123, with maximum LOD scores of
2.54, 2.06, and 2.60, respectively. For all other markers, p11.3, as well as to the markers closely linked to the
red and green cone–pigment genes (RCP and GCP, re-at least one recombination event between the XPLCD
locus and these markers was observed, resulting in nega- spectively) in Xq28. The COD1 gene region was ana-
lyzed by multipoint linkage analysis including the mark-tive LOD scores in two-point linkage analysis. Analysis
of the Xq27 haplotypes suggests that the XLPCD locus
in this family is located in the chromosomal region be-
tween the loci DXS292 and DXS1113 (ﬁg. 1).
Two-point linkage analysis with different combina-
tions of several distinct markers along the entire X chro-
mosome resulted in negative or low LOD scores along
the chromosome, except for the Xq27 region. Signiﬁcant
linkage without recombination was found between the
COD2 locus and the markers DXS297, DXS998, and
DXS1123, with LOD scores of 2.54, 2.06, and 2.60,
respectively.
Multipoint linkage analysis with different combina-
tions of markers yielded negative multipoint LOD scores
along the entire chromosome, except for marker combi-
Figure 2 Multipoint analysis of the XLPCD locus. Map dis-nations in the Xq27 region, and thus resulted in exclu-
tances (horizontal axis) between the markers used were 3 cM forsion of the position of the disease locus elsewhere.
DXS292–DXS1123 and 5 cM for DXS1123–DXS1113, as summa-Multipoint linkage analysis suggests that COD2 is lo-
rized from the genetic maps from the Genome Database and CEPH
cated between DXS292 and DXS1113, with a maximum and from the physical map of the region as presented on the Internet
multipoint LOD score of 10.8 at the DXS1123 locus by the Whitehead Institute. DXS292 is present on the consensus map
of the X chromosome.(ﬁg. 2).
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ers DMD49, DYS-I, DXS1058, MAOB, and DXS255. quently, the results presented here provide evidence for
genetic heterogeneity in XLPCD. This conﬁrms the state-In the entire interval, multipoint LOD scores were õ0
(results not shown). ment of Verdoorn and Pinckers (1988), who put for-
ward the possible existence of more than one type of X-The possible involvement of the RCP and GCP genes
in the XLPCD in this family was checked by analysis of linked cone dystrophy. The clinical differences observed
in XLPCD may reﬂect an equally heterogeneous situa-the segregation patterns of two markers, one distally
and one proximally very closely linked to this gene clus- tion at the molecular level. Similarly to other genetic eye
diseases, such as retinitis pigmentosa, ‘‘progressive coneter. Both markers, DXS8103 and DXS8069, reveal re-
combination events with the XLPCD locus. Conse- dystrophy’’ may be a term to describe a group of diseases
caused by distinct defects in one of multiple genes scat-quently, multipoint linkage analysis including these
markers resulted in negative LOD scores as well (not tered along the human genome.
shown). In addition, Southern blot analysis with an
RCP/GCP cDNA probe (kindly provided by J. Nathans)
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